Pfizer-Allergan $160 bn deal: Interesting facts and outcomes
Pfizer-Allergan $160 bn deal: Interesting facts and outcomes

Let's take a look at some of the interesting facts from the record USD 160 billion deal.

Pfizer to buy Allergan in $160 bn deal to create world's biggest drugmaker
Pfizer to buy Allergan in $160 bn deal to create world's biggest drugmaker

Pfizer Inc, the maker of Viagra and Lipitor, has struck a deal to buy Botox-maker Allergan in a transaction valued at about $160 billion, creating the world's biggest drugmaker.

Investors seek protection against healthcare stock decline

Healthcare companies on a seven-year tear have been top performers so far in 2015, helping to push broad stock indexes to record levels, but traders are now looking to protect themselves from a selloff as they await major earnings reports in the sector.

Pfizer breast cancer drug gets early FDA approval

Federal health regulators have approved a highly anticipated medicine from Pfizer Inc to treat postmenopausal women with a certain type of advanced breast cancer who have not already taken other drugs.

U.S. multinationals hit hard by strong dollar, to bleed further into 2015

A slew of U.S. multinational companies, from DuPont to Procter & Gamble, showed that a strong U.S. dollar hurt their earnings, and several blue-chip exporters said the situation will get worse if the greenback holds its strength.

Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor

Pfizer Inc and India`s Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.

AstraZeneca fights Pfizer bid by predicting sales surge

AstraZeneca Plc laid out its defence against Pfizer Inc`s USD 106-billion takeover approach on Tuesday by predicting its sales would rise by three quarters over the next decade, although only after a short-term drop.

Pfizer sales way off mark as company pursues AstraZeneca

Pfizer Inc reported quarterly revenue well below Wall Street expectations on falling sales of generic medicines, underscoring its interest in pursuing a USD 106 billion bid for rival AstraZeneca to promote new business growth.

Pfizer files patent suit against Lupin, 5 other pharma firms

US-based pharma giant Pfizer Inc on Tuesday said it has filed suit against six firms, including India's Lupin, over patent infringement of celecoxib, the active ingredient of its branded drug Celebrex used for treating osteoarthritis.

Pfizer appoints Aijaz Tobaccowalla as India Managing Director

Drug firm Pfizer Ltd, the Indian arm of global major Pfizer Inc, on Thursday said it has appointed Aijaz Tobaccowalla as the Managing Director to replace Kewal Handa, who had earlier this year announced his intention to retire in August 2012.

Birth control pills recall raises risk of unplanned pregnancy

Pfizer Inc is reaching out directly to women consumers to warn them about its US recall of one million packets of birth control pills.